Fluconazole + Ivermectin Tablet Franchise in Ahmedabad

Antifungal & Antiparasitic Tablet Supplier in Mumbai

Infection Control Medicine Distributor in Delhi

Antifungal & Parasite Care Pharma Franchise in Bangalore

Fluconazole Ivermectin Tablet Stockist in Hyderabad
Broad-Spectrum Infection Care Tablet Manufacturer & Exporter in Chandigarh

Home/Products /fluconazole-150mg-ivermectin-6mg-tablet

Fucoziff IM Tablet

Composition : Fluconazole (150mg) + Ivermectin (6mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10x5

Price : ₹0/-

Fucoziff IM Tablet contains Fluconazole 150mg + Ivermectin 6mg, a dual-action therapy for managing fungal and parasitic infections effectively. Fluconazole combats fungal overgrowth, while Ivermectin eliminates parasitic infestations, providing comprehensive infection control.

This combination is clinically preferred due to its broad-spectrum efficacy and patient tolerability, ensuring reliable results for acute and chronic infections. Patients experience faster recovery, reduced infection recurrence, and improved overall health.

For franchise partners, Fucoziff IM Tablet is a high-demand product in the antifungal and antiparasitic segment, offering strong market acceptance and consistent repeat prescriptions. Its dual-action formula makes it a profitable addition to specialty portfolios, boosting sales and business growth.

With rising incidences of fungal and parasitic infections, Fucoziff IM Tablet provides sustainable business opportunities, helping partners expand their footprint in infection care therapy.


Read More

About the Product

Fucoziff IM Tablet contains Fluconazole 150mg + Ivermectin 6mg, a dual-action therapy for managing fungal and parasitic infections effectively. Fluconazole combats fungal overgrowth, while Ivermectin eliminates parasitic infestations, providing comprehensive infection control.

This combination is clinically preferred due to its broad-spectrum efficacy and patient tolerability, ensuring reliable results for acute and chronic infections. Patients experience faster recovery, reduced infection recurrence, and improved overall health.

For franchise partners, Fucoziff IM Tablet is a high-demand product in the antifungal and antiparasitic segment, offering strong market acceptance and consistent repeat prescriptions. Its dual-action formula makes it a profitable addition to specialty portfolios, boosting sales and business growth.

With rising incidences of fungal and parasitic infections, Fucoziff IM Tablet provides sustainable business opportunities, helping partners expand their footprint in infection care therapy.


Common side effects may include nausea, vomiting, headache, dizziness, or mild gastrointestinal disturbances. Some patients may experience transient skin rashes, fatigue, or liver enzyme changes. Severe or persistent reactions should be reported immediately to a healthcare professional.

Fucoziff IM Tablet is indicated for the treatment of fungal infections such as candidiasis and dermatophytosis, as well as parasitic infections including strongyloidiasis, scabies, and other susceptible parasitic infestations. It helps clear infections efficiently and reduces associated symptoms such as itching, inflammation, and discomfort.

Fucoziff IM Tablet should be taken strictly under medical supervision. It is contraindicated in patients with known hypersensitivity to Fluconazole, Ivermectin, or any component of the formulation. Liver function should be monitored during prolonged therapy, and caution is advised in patients with liver or kidney impairment.

Store Fucoziff IM Tablet in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep out of reach of children and do not use after the expiry date mentioned on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation